Interventional device manufacturer Boston Scientific of Natick, MA, reported that the Food and Drug Administration has approved enhancements to the directions for use (DFU) of its Taxus Express2 paclitaxel-eluting coronary stent system, indicating that patients receiving the stent systems may safely undergo an MRI immediately following implantation.
The company claimed that Taxus is the first drug-eluting stent to receive approval for immediate postprocedure MRI. Boston Scientific's Express2 stent system also received approval for immediate MRI exams, according to the company.
Patients receiving coronary stents have typically been required to wait approximately two months before receiving an MRI, Boston Scientific said.
By AuntMinnie.com staff writers
April 5, 2005
Related Reading
Boston Scientific loses stent verdict, March 25, 2005
Boston Scientific continues robust growth, February 1, 2005
Court issues judgment in stent patent dispute, January 6, 2005
Boston Scientific provides tsunami aid, December 31, 2004
Boston Scientific to acquire AST, December 17, 2004
Copyright © 2005 AuntMinnie.com
